Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10330376" target="_blank" >RIV/00064165:_____/16:10330376 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/16:00091587 RIV/00216208:11110/16:10330376 RIV/65269705:_____/16:00066153
Result on the web
<a href="http://dx.doi.org/10.1080/14737140.2016.1247699" target="_blank" >http://dx.doi.org/10.1080/14737140.2016.1247699</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/14737140.2016.1247699" target="_blank" >10.1080/14737140.2016.1247699</a>

Result language
angličtina
Original language name
Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management
Original language description
Introduction: Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pathomorphologically and immunohistochemically detectable lesion which biological significance and clinical relevance is unknown. Areas covered: We investigate methods of STIC diagnostics and we present an overview of recent studies and available knowledge on surgical management, adjuvant chemotherapy and subsequent follow-up procedure in women with an isolated STIC. Expert commentary: Patients found to have an incidental STIC lesion should be referred for screening of BRCA1/2 mutation. In absence of an invasive disease, follow-up of patient remains a reasonable choice. A rational scheme should include check-ups every 6 months consisting of gynecological examinations, CA 125 and/or HE4 and pelvic ultrasound examination by an expert sonographer.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NV15-27695A" target="_blank" >NV15-27695A: Characterization of genetic predisposition to ovarian cancer using Next Gene Sequencing analysis</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)